Navigation Links
More than just a kinase: CDK6 in cancer
Date:8/13/2013

Cancer in humans is frequently associated with unusually high amounts of one or more proteins responsible for controlling the rate at which cells divide. As an example, excessive amounts of the cyclin-dependent kinase CDK6 are often found in types of cancer such as lymphoma. Together with a number of collaborators within Vienna and beyond, Karoline Kollmann of the University of Veterinary Medicine, Vienna (Vetmeduni) has now shown that CDK6 is part of a multiprotein complex that stimulates the production of one of the so-called INK4 family members (confusingly termed p16INK4a), which suppresses tumour growth. In other words, the cell has an inbuilt mechanism to help it cope with excessive amounts of CDK6.

The problems really start when p16INK4a is missing, as is frequently the case in lymphomas or leukaemias. Now the high levels of CDK6 are unchecked and so can lead directly to a stimulation of cell division. Furthermore, Kollmann and her colleagues showed that another CDK6-containing complex can also promote the production of an additional factor, known as VEGF-A, that increases the growth of blood vessels and thus ensures that the cells in the growing tumours are supplied with sufficient energy and oxygen to multiply. CDK6 is the first factor to be shown to be involved in regulating tumour growth while simultaneously helping to supply tumours with blood.

As its name implies, CDK6 is a kinase, i.e. it adds phosphate groups to other proteins and thereby alters their activity. In a further twist to the tail, the Vetmeduni scientists have shown that CDK6 can still exert its effects on p16INK4a and VEGF-A when it lacks its kinase activity: a mutant form of the CDK6 protein with the kinase function inactivated retains the ability to regulate expression of the p16INK4a and VEGF-A genes.

Veronika Sexl, Head of the Vetmeduni's Institute of Pharmacology and Toxicology, where the work was performed, notes the medical importance of her group's findings. "Because it is known to be involved in so many cancers, CDK6 represents a promising target for anti-cancer therapy and lots of labs are trying to design specific inhibitors. But their efforts are focused on inhibiting CDK6's kinase function. We have shown that CDK6 has an additional, kinase-independent mode of action that is responsible for the uncontrolled cell growth and increased production of blood vessels that are a hallmark of cancer. CDK6 inhibitors will also need to block this new function if they are to be effective in treating cancer."


'/>"/>

Contact: Susanna Kautschitsch
susanna.kautschitsch@vetmeduni.ac.at
43-125-077-1153
University of Veterinary Medicine -- Vienna
Source:Eurekalert

Related biology news :

1. Perception of fertility affects quality of life in young, female cancer survivors
2. New evidence that cancer cells change while moving throughout body
3. With early, obvious benefit of a targeted cancer drug, should expensive clinical testing continue?
4. Protein involved in nerve-cell migration implicated in spread of brain cancer
5. Breast cancer surgery linked to swollen arm syndrome
6. Cancer research implies future for personalized medicine, reduction in animal testing
7. Illinois scientists put cancer-fighting power back into frozen broccoli
8. Scientists learn how soy foods protect against colon cancer
9. Percentage of cancers linked to viruses potentially overestimated
10. Mechanism offers promising new approach for harnessing the immune system to fight cancer
11. HudsonAlpha and UAB researchers work to identify optimal treatments for ER+ breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):
(Date:8/15/2017)... ... August 15, 2017 , ... ... accelerate pharmaceutical and biotherapeutics development, announces the launch of the new NHS ... to gain kinetic binding data for a wide range of molecules, including small ...
(Date:8/15/2017)... (PRWEB) , ... August 15, 2017 , ... The ... time on Immuno-Oncology 360° (IO360°) programming through a series of upcoming panels and events. ... February 7-9, 2018, at The Roosevelt Hotel in New York City. , “With our ...
(Date:8/14/2017)... Portland, Oregon (PRWEB) , ... August 14, 2017 ... ... modules that provide essential device-to-computer interconnect using USB or PCI Express, announced the ... hardware. , SYZYGY is intended to satisfy the need for a compact, low ...
(Date:8/11/2017)... ... ... Algenist continues to disrupt the skincare industry with today’s debut of GENIUS Liquid ... the key structural element skin needs to maintain its youthful appearance and Algenist is ... First to market with proprietary collagen water active , Active ...
Breaking Biology Technology: